A novel small-molecule inhibitor targeting the IL-6 receptor β subunit, glycoprotein 130

Journal of Immunology

Volumn 195, Issue 1, 2015, Pages 237-245

  Hong, Soon Sun ^a   Choi, Jung Ho ^b,i   Lee, Sung Yoon ^c   Park, Yeon Hwa ^d   Park, Kyung Yeon ^d   Lee, Joo Young ^d   Kim, Juyoung ^a   Gajulapati, Veeraswamy ^c   Goo, Ja Il ^c   Singh, Sarbjit ^c   Lee, Kyeong ^e   Kim, Young Kook ^b   Im, So Hee ^f   Ahn, Sung Hoon ^g   Rose John, Stefan ^h   Heo, Tae Hwe ^d   Choi, Yongseok ^c  

^a Inha University School of Medicine   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Korea University   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Dongguk University   (South Korea)

^f Chungnam National University   (South Korea)

^g Kangwon National University   (South Korea)

^h UNIVERSITY OF KIEL   (Germany)

ⁱ Korea Shipbuilding Offshore Engineering Co   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ALPHA; JANUS KINASE 2; LEUKEMIA INHIBITORY FACTOR; LMT 28; METHOTREXATE; OXAZOLIDINONE DERIVATIVE; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; GLYCOPROTEIN GP 130; IL6ST PROTEIN, MOUSE; JAK2 PROTEIN, MOUSE; LMT-28; MOLECULAR LIBRARY; NONSTEROID ANTIINFLAMMATORY AGENT; STAT3 PROTEIN, MOUSE;

ACUTE PANCREATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; BAGG ALBINO MOUSE; DBA MOUSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; IMMUNOLOGY; LEUKOCYTE; MOLECULAR LIBRARY; ORAL DRUG ADMINISTRATION; PANCREATITIS; PATHOLOGY; PHARMACOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; CELL LINE, TUMOR; CYTOKINE RECEPTOR GP130; GENE EXPRESSION REGULATION; HEP G2 CELLS; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; LEUKOCYTES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; OXAZOLIDINONES; PANCREATITIS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84932163442     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402908     Document Type: Article

References (42)

1. Sengupta, T. K., E. M. Schmitt, and L. B. Ivashkiv. 1996. Inhibition of cytokines and JAK-STAT activation by distinct signaling pathways. Proc. Natl. Acad. Sci. USA 93: 9499-9504.
2. Wolf, J., S. Rose-John, and C. Garbers. 2014. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 70: 11-20.
3. Calabrese, L. H., and S. Rose-John. 2014. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 10: 720-727.
4. Yao, X., J. Huang, H. Zhong, N. Shen, R. Faggioni, M. Fung, and Y. Yao. 2014. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol. Ther. 141: 125-139.
5. Scheller, J., C. Garbers, and S. Rose-John. 2014. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin. Immunol. 26: 2-12.
6. Mihara, M., M. Hashizume, H. Yoshida, M. Suzuki, and M. Shiina. 2012. IL-6/ IL-6 receptor system and its role in physiological and pathological conditions. Clin. Sci. 122: 143-159.
7. Jones, S. A., J. Scheller, and S. Rose-John. 2011. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121: 3375-3383.
8. Zinzalla, G., M. R. Haque, B. P. Basu, J. Anderson, S. L. Kaye, S. Haider, F. Hasan, D. Antonow, S. Essex, K. M. Rahman, et al. 2010. A novel smallmolecule inhibitor of IL-6 signalling. Bioorg. Med. Chem. Lett. 20: 7029-7032.
9. Jenkins, B. J., A. W. Roberts, C. J. Greenhill, M. Najdovska, T. Lundgren-May, L. Robb, D. Grail, and M. Ernst. 2007. Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. Blood 109: 2380-2388.
10. Leu, C.-M., F.-H. Wong, C. Chang, S.-F. Huang, and C.-P. Hu. 2003. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 22: 7809-7818.
11. Fischer, M., J. Goldschmitt, C. Peschel, J. P. Brakenhoff, K.-J. Kallen, A. Wollmer, J. Grötzinger, and S. Rose-John. 1997. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat. Biotechnol. 15: 142-145.
12. Xu, S., and N. Neamati. 2013. gp130: a promising drug target for cancer therapy. Expert Opin. Ther. Targets 17: 1303-1328.
13. Bellido, T., N. Stahl, T. J. Farruggella, V. Borba, G. D. Yancopoulos, and S. C. Manolagas. 1996. Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. J. Clin. Invest. 97: 431-437.
14. Heymann, D., A. Godard, S. Raher, N. Bentouimou, F. Blanchard, M. Cherel, M. M. Hallet, and Y. Jacques. 1996. Leukemia inhibitory factor (LIF) and oncastsin M (OSM) high affinity binding require additional receptor subunits besides GP130 and GP190. Cytokine 8: 197-205.
15. Boulanger, M. J., D.-C. Chow, E. E. Brevnova, and K. C. Garcia. 2003. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 300: 2101-2104.
16. Quan, L.-D., G. M. Thiele, J. Tian, and D. Wang. 2008. The development of novel therapies for rheumatoid arthritis. Expert Opin. Ther. Pat. 18: 723-738.
17. Hashizume, M., and M. Mihara. 2011. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis (Egypt) 2011: 765624.
18. Brahn, E., M. L. Banquerigo, G. S. Firestein, D. L. Boyle, A. L. Salzman, and C. Szabó. 1998. Collagen induced arthritis: reversal by mercaptoethylguanidine, a novel antiinflammatory agent with a combined mechanism of action. J. Rheumatol. 25: 1785-1793.
19. Nawata, Y., E. M. Eugui, S. W. Lee, and A. C. Allison. 1989. IL-6 is the principal factor produced by synovia of patients with rheumatoid arthritis that induces B-lymphocytes to secrete immunoglobulins. Ann. N. Y. Acad. Sci. 557: 230-238, discussion 239.
20. Zyromski, N., and M. M. Murr. 2003. Evolving concepts in the pathophysiology of acute pancreatitis. Surgery 133: 235-237.
21. Norman, J., M. Franz, J. Messina, A. Riker, P. J. Fabri, A. S. Rosemurgy, and W. R. Gower, Jr. 1995. Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery 117: 648-655.
22. Fu, K., M. P. Sarras, Jr., R. C. De Lisle, and G. K. Andrews. 1997. Expression of oxidative stress-responsive genes and cytokine genes during caerulein-induced acute pancreatitis. Am. J. Physiol. 273: G696-G705.
23. Suzuki, S., K. Miyasaka, A. Jimi, and A. Funakoshi. 2000. Induction of acute pancreatitis by cerulein in human IL-6 gene transgenic mice. Pancreas 21: 86-92.
24. Zhang, H., P. Neuhöfer, L. Song, B. Rabe, M. Lesina, M. U. Kurkowski, M. Treiber, T. Wartmann, S. Regnér, H. Thorlacius, et al. 2013. IL-6 transsignaling promotes pancreatitis-associated lung injury and lethality. J. Clin. Invest. 123: 1019-1031.
25. Gabay, C., P. Emery, R. van Vollenhoven, A. Dikranian, R. Alten, K. Pavelka, M. Klearman, D. Musselman, S. Agarwal, J. Green, and A. Kavanaugh, ADACTA Study Investigators. 2013. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, doubleblind, controlled phase 4 trial. [Published erratum appears in 2013 Lancet. 381: 1540.] Lancet 381: 1541-1550.
26. Mintz, C. S., and R. Crea. 2013. Protein scaffolds the next generation of protein therapeutics? Bioprocess Int. 11: 40-48.
27. Terstegen, L., P. Gatsios, J. G. Bode, F. Schaper, P. C. Heinrich, and L. Graeve. 2000. The inhibition of interleukin-6-dependent STAT activation by mitogenactivated protein kinases depends on tyrosine 759 in the cytoplasmic tail of glycoprotein 130. J. Biol. Chem. 275: 18810-18817.
28. Hayashi, M., M.-C. Rho, A. Enomoto, A. Fukami, Y.-P. Kim, Y. Kikuchi, T. Sunazuka, T. Hirose, K. Komiyama, and S. Omura. 2002. Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130. Proc. Natl. Acad. Sci. USA 99: 14728-14733.
29. Sengupta, T. K., E. S. Talbot, P. A. Scherle, and L. B. Ivashkiv. 1998. Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogenactivated protein kinases. Proc. Natl. Acad. Sci. USA 95: 11107-11112.
30. Terstegen, L., B. G. Maassen, S. Radtke, I. Behrmann, F. Schaper, P. C. Heinrich, L. Graeve, and P. Gatsios. 2000. Differential inhibition of IL-6-type cytokineinduced STAT activation by PMA. FEBS Lett. 478: 100-104.
31. Xu, S., F. Grande, A. Garofalo, and N. Neamati. 2013. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Mol. Cancer Ther. 12: 937-949.
32. Kim, H. S., A. R. Kim, H. J. Park, D. K. Park, K. Kim, N. Y. Ko, B. Kim, D. K. Choi, H. S. Won, W. S. Shin, et al. 2011. Morus bombycis Koidzumi extract suppresses collagen-induced arthritis by inhibiting the activation of nuclear factor-kB and activator protein-1 in mice. J. Ethnopharmacol. 136: 392-398.
33. Lu, Z. Y., J. Brochier, J. Wijdenes, H. Brailly, R. Bataille, and B. Klein. 1992. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur. J. Immunol. 22: 2819-2824.
34. Koul, A., E. Arnoult, N. Lounis, J. Guillemont, and K. Andries. 2011. The challenge of new drug discovery for tuberculosis. Nature 469: 483-490.
35. Saleh, A. Z. M., K. L. Greenman, S. Billings, D. L. Van Vranken, and J. J. Krolewski. 2005. Binding of madindoline A to the extracellular domain of gp130. Biochemistry 44: 10822-10827.
36. Murakami, M., M. Hibi, N. Nakagawa, T. Nakagawa, K. Yasukawa, K. Yamanishi, T. Taga, and T. Kishimoto. 1993. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260: 1808-1810.
37. Gearing, D. P., C. J. Thut, T. VandeBos, S. D. Gimpel, P. B. Delaney, J. King, V. Price, D. Cosman, and M. P. Beckmann. 1991. Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130. EMBO J. 10: 2839-2848.
38. Scheinecker, C., J. Smolen, U. Yasothan, J. Stoll, and P. Kirkpatrick. 2009. Tocilizumab. Nat. Rev. Drug Discov. 8: 273-274.
39. O'Dell, J. R., C. E. Haire, N. Erikson, W. Drymalski, W. Palmer, P. J. Eckhoff, V. Garwood, P. Maloley, L. W. Klassen, S. Wees, et al. 1996. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 334: 1287-1291.
40. Takagi, N., M. Mihara, Y. Moriya, N. Nishimoto, K. Yoshizaki, T. Kishimoto, Y. Takeda, and Y. Ohsugi. 1998. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 41: 2117-2121.
41. Yamamoto, M., K. Yoshizaki, T. Kishimoto, and H. Ito. 2000. IL-6 is required for the development of Th1 cell-mediated murine colitis. J. Immunol. 164: 4878-4882.
42. Yoshida, K., T. Taga, M. Saito, S. Suematsu, A. Kumanogoh, T. Tanaka, H. Fujiwara, M. Hirata, T. Yamagami, T. Nakahata, et al. 1996. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc. Natl. Acad. Sci. USA 93: 407-411.